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Thirty years of coronary angioplasty
On September 15th of last year, Adolph Black-
man, a 70-year-old retired insurance salesman, sto-
od before a group of cardiologists in Zurich and in-
troduced himself. But he needed no introduction.
Thirty years before, he and many of these same
cardiologists had shared a historical moment, perhaps
as important in our lifetime as when, over 150 years
before, Dr. John Warren applied Morton’s discove-
ry and painlessly removed a tumour from the neck
of a young girl before a group of surgeons in Bo-
ston. At both procedures, the observing physicians
realized they were witnessing something that wo-
uld change medicine forever. Thirty years before,
this healthy salesman had been disabled by angina
and in front of many of these same cardiologists had
undergone the first coronary angioplasty. He was
now in Zurich to celebrate that event and to celebra-
te the visionary physician, Andreas Gruentzig, who-
se dream and dedication as well as technical skill had
made it possible. Today, over one million percuta-
neous interventions are performed each year in co-
ronary arteries and in almost every important arte-
ry in the body as a direct result of this concept.
To understand the importance of that event,
one has to understand the limitations of the thera-
py for coronary artery disease and its consequen-
ces, angina and myocardial infarction, in the late
1970s. There were very few tools for the manage-
ment of angina at that time. Although the role of
lipid metabolism was appreciated, the pharmacolo-
gy available to normalize the lipids was inadequate.
Beta blockers and nitroglycerine, and perhaps an-
ticoagulation, were the major weapons available.
The importance of thrombosis was not appreciated
and myocardial infarctions were thought to be the
result of coronary spasm. The value of aspirin as
an antiplatelet agent had yet to be understood. Cal-
cium channel blockers, long-acting nitroglycerine
preparations and ACE inhibitors were not available.
The most effective approach was a drastic lifestyle
change with a nearly fat-free diet. Bypass surgery
was reserved for multivessel disease and even here
it was controversial as no studies had yet been re-
ported showing any longevity advantage for surge-
ry over medical therapy. Surgery for lesser dise-
ase was performed only reluctantly because of the
likely need for additional surgery, so patients had
to live with considerable angina before this could
be considered.
One year before, Gruentzig had presented
a poster at the American Heart Association (AHA)
meeting. As related by David Faxon in a recent inte-
rview [1] “one poster was completely crowded with
people. A tall Swiss guy was presenting a crazy idea.
He had ligated the LAD of a dog and put a balloon
in it. That is crazy, but boy is that interesting.” At
that time putting anything into the coronary arte-
ries was absolutely forbidden. The reception was
quite mixed; most physicians thought he was cra-
zy, but a few were intrigued. The next year in 1977
when the results of the procedure on Mr. Blackman
were reported, also at the AHA meeting, it was stan-
ding room only and after the presentation, the au-
dience stood and applauded, almost unheard of at
scientific meetings. The procedure was named per-
cutaneous transluminal coronary angioplasty (PTCA)
modifying the terminology introduced by Dotter to
describe percutaneous peripheral lesion dilation.
Andreas Guentzig was born in Dresden, Ger-
many on June 25th 1939. His father died as a pilot in
the Luftwaffe during the war. After the war the East
German state planned for him to become a bricklay-
er, but his mother escaped with Andreas and his
sister (who became a professor of ophthalmology)
to West Germany. He graduated from the Univer-
sity of Heidelberg in 1969 and he trained as an in-
terventional radiologist. With Eberhard Zietler he
performed a large number of peripheral angiopla-
sties using the Dotter coaxial tubular catheter me-
chanism. Gruentzig became interested in perfor-
ming angioplasties on coronary arteries but he re-
alized that the Dotter technique was not suited to
that site. As detailed in the excellent history by
Gary Roubin [2], the breakthrough occurred in 1974
when, together with Professor Hoyt — a plastics
engineer from the Technical University of Zurich,
he was able to develop a balloon made of PVC which
could form a “sausage shape” of a predetermined
diameter at a given pressure. This protected the
normal areas around the lesion from damage while
concentrating the energy on the lesion (the previo-
us balloon material, latex, tended to “dogbone” and
damage the “normal” artery surrounding the le-
sion). He created a double lumen catheter by pla-
cing one catheter inside another and then folding
the outside one by meticulously running a tool down
it to create a “v” so it would not collapse under suc-
tion. His workshop was the kitchen in his home [3].
The development of equipment proceeded slowly
at first. A small Swiss company, Schneider, known
for its needles, was chosen to manufacture it. The
original catheter was manufactured in a garage with
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an output of 5 balloons per week, all handmade.
Guiding catheters had to be designed. Gruentzig
controlled every aspect of the manufacture and
quality control. As recalled by Heliane Canepa [4],
who later went on to become president of Schne-
ider Worldwide, “Gruentzig was just a winner
— a winner personality. He was obsessed with his
invention. He was a very serious character, very
good-hearted but very demanding. He wanted the
prototypes, he wanted it safe. He was a very tech-
nical person, so he could talk to the engineers on
a technical basis.”
He also totally controlled the use of the cathe-
ter. In the beginning, in order to get a balloon ca-
theter, a would-be angioplastier had to attend a co-
urse and then contribute data to a registry which
monitored every use — no data, no balloon. Gru-
entzig protected and nurtured the procedure, so the
procedure began slowly but with good results.
An early challenge was training the cardiology
community in the new technique. Taking a clue
from the surgical demonstrations of the nineteenth
century, he pioneered the live demonstration co-
urse. The patients were presented and the proce-
dures performed live; success or failure was not
known before the procedure. Spencer King likened
the atmosphere to that of a stock car race, in which
the spectator watched not to see the cars race aro-
und the track but for the crash [4]. The real learning
occurred when Gruentzig dealt with the problem, the
crash, in “real time” (and usually solved it). He was
a gifted teacher and impressed all who knew him.
In 1980 Gruentzig left Zurich and moved to the
Emery School of Medicine in Atlanta, Georgia,
where he was appointed Professor of Medicine and
was fully supported in his efforts to promote and
develop the procedure. The live demonstration co-
urse was refined into the form in which it remains
to this day. TV cables were drawn between the cath
lab and a large auditorium. There would be a mini-
mum of three feeds, one of the operator talking to
the audience, one of his hands and one from the
monitor in the room, so the audience could see what
Gruentzig saw. There was a moderator in the room,
always a skilled interventionalist, asking questions
so all the decisions were transparent and discus-
sed with the audience. In addition, the audience
could query Andreas in real time. These courses
were extremely well attended by all cardiac angio-
graphers prior to starting their own programs and
were widely copied by others in the years that fol-
lowed. Even now, major meetings arrange for sa-
tellite transmission of procedures from the US and
international laboratories for live transmissions.
On October 29th 1985, a year that saw the de-
aths of angiographic pioneers Melvin Judkins and
Mason Sones, Andreas Gruentzig, as his father had
done before him, died at the controls of his plane,
flying from St. Simon Island to Atlanta in a rainstorm
for a Monday case.
But his legacy did not end with his death, sin-
ce plans were underway for an NIH grant to com-
pare PTCA with coronary artery bypass grafting
(CABG) in patients with multivessel disease. This
grant was pursued after his death and the study
completed by King and colleagues at Emery. It sho-
wed that the survival rate was similar in patients
who were randomized to PTCA and CABG.
The present success of angioplasty owes much
to the man, Andreas Gruentzig, his charisma and
his careful stewardship of the development and pro-
motion of the technique. According to Dr. King, his
watchword was “don’t exceed your capabilities —
stay within what you can do” [5]. After conceiving
the procedure and carefully developing the early
tools, he courageously worked in the open to mini-
mize scepticism, willing to discuss the cases. He
emphasized scientific validation with randomized
trials. He pioneered the concept of a registry of all
procedures to monitor results and maintain quali-
ty. This concept was central to the organization of
the Society for Cardiac Angiography [now the So-
ciety for Cardiac Angiography and Interventions
(SCAI)] and most recently to the American Colle-
ge of Cardiology in the National Cardiovascular Data
Registry (NCDR), with several million procedures
recorded. He pioneered the live demonstration co-
urse, a technique which has proven its value over
time and which facilitated the rapid and widespre-
ad introduction of these new techniques. And first
and foremost, “he was a doctor. His first concern
was: was it appropriate to do it? Most of the time
(in discussion) was spent discussing the manage-
ment of the patient, then the details of the proce-
dure” [1].
So, in Zurich, while the celebration was for
30 years of a technique that revolutionised the ma-
nagement of coronary disease, even more, it was
a celebration of the genius of one man who had
a dream and pursued and nurtured it so that it co-
uld properly develop to benefit us all.
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